Key points from article :
Clene Nanomedicine developed a new class of neuro-therapeutics called nanocatalysts.
Completed a $42 million Series D financing last summer.
"Oral, water-based nanotherapeutic based on metals may have disease treating benefits.” - Rob Etherington, CEO of Clene Nanomedicine.
Using clean-surfaced metallic nanocrystals to target conditions is completely unique.
“Make highly faceted, clean-surfaced gold nanocrystals and use them in pharmaceutical applications,” - Etherington.
Bioenergetic gold-based nanocatalyst accelerate neurorepair for patients with neurodegenerative disease.
Concluded all of the safety and toxicity work, and is now in a number of clinical studies.
"We can potentially reverse amyotrophic lateral sclerosis, multiple sclerosis (MS) and Parkinson’s disease,” - Etherington.
Phase 2 trials for both MS and Parkinson’s designed to prove that CNM-Au8 is driving biological energetic reactions.
“The goal is to build a Phase 3 study to evaluate the investigational products.” - Etherington.
